Skip to main content

Latest News

NICE approves use of new treatment for advanced metastatic bladder cancer

Enfortumab Vedotin combined with Pembrolizumab will now be available for eligible patients in the UK

The British Association of Urological Surgeons (BAUS) welcomes the decision by the National Institute for Health and Care Excellence (NICE) to approve the use of combination therapy enfortumab vedotin (Padcev) with pembrolizumab as a first-line treatment for untreated unresectable or metastatic urothelial (bladder) cancer in patients who are eligible for platinum-based chemotherapy. Urothelial cancer affects cells that form the inner...

Upcoming Event

6 – 10 Oct 2025

The 10th Urology Simulation Boot Camp 2025

The Bridge Community Church, Rider Street, Leeds LS9 7BQ

Course Programme  Directions